The global biotechnology market was valued at USD 1,376.1 billion in 2025 and is projected to grow from USD 1,491.5 billion in 2026 to USD 4,334.8 billion by 2034, at a compound annual growth rate (CAGR) of 14.3% during the forecast period (2026–2034).

Biotechnology broadly refers to the application of biological systems and living organisms to develop products that improve healthcare, agriculture, industry, and the environment. Market expansion is being driven by wider adoption across sectors beyond healthcare, accelerated innovation in genomics and gene editing, rising R&D investment, and strong government support.

Key Market Drivers & Restraints

Driver — Biopharmaceutical Demand: Biopharmaceutical drugs offer higher efficacy, better target specificity, and improved safety over traditional small molecule drugs. Six of the top ten best-selling drugs in H1 2025 were biopharmaceuticals — including Keytruda, Mounjaro, Dupixent, Skyrizi, Darzalex, and Opdivo — underscoring the clinical and commercial dominance of biologics.

Restraint — High R&D Costs: Developing biologics requires USD 2–4 billion and 10–12 years on average, compared to USD 1–2 billion and 8–10 years for small molecule drugs. The high failure rate in biotech product development further amplifies financial risk.

Opportunity — Sustainable Biotech: A global transition toward low-carbon, resource-efficient production is creating lucrative opportunities for industrial biotech through bio-based chemicals, enzymes, and advanced biofuels that comply with tightening environmental regulations.

Challenge — Regulatory Complexity: Companies must navigate differing regulatory frameworks across geographies. A therapy approved by the U.S. FDA may still require additional clinical data for EMA or India's CDSCO approval, fragmenting global launch strategies and increasing costs.

More Details: https://www.fortunebusinessinsights.com/biotechnology-market-116041

Market Trends

Single-Use Manufacturing: Single-use and flexible manufacturing systems are a leading trend, having been adopted in 87% of biopharma manufacturing facilities in 2024. These systems reduce cleaning requirements, allow multi-product operations, and lower contamination risk, enabling faster time-to-market.

AI in Biotechnology: AI is transforming target identification and drug development. Tasks that previously took 3–6 years can now be accomplished in 1–2 years using AI tools. Insilico Medicine, for example, developed a novel drug candidate for idiopathic pulmonary fibrosis in just 18 months.

Segmentation Highlights

By Technology: Bioprocessing technologies led the market in 2025, fueled by rising biologics demand and new facility investments (e.g., FUJIFILM's USD 1.2 billion CDMO expansion in North Carolina). The genomics & genetic analysis segment is expected to grow at a CAGR of 12.1%.

By Application: Biopharmaceutical discovery & preclinical research dominated in 2025, supported by PhRMA member R&D spend that has consistently exceeded USD 100 billion annually. The cell & gene therapy segment is the fastest-growing, projected at a CAGR of 19.7%.

By End-User: Pharmaceutical & biotechnology companies held the largest share, projected at 53.8% in 2026. CROs & CDMOs are the fastest-growing end-user segment, expected to expand at a CAGR of 17.5%.

Regional Outlook

North America leads globally, with a 43.34% market share in 2025, driven by strong biopharma R&D and advanced manufacturing. China is among the fastest-growing countries, projected at USD 88.3 billion in 2026.

Investment Landscape

Venture capital funding in biopharmaceuticals reached approximately USD 34 billion in 2025, a recovery that grew around 6% year-on-year, though still well below the USD 56 billion peak of 2021. Notable 2024 VC rounds included USD 1 billion for Xaira Therapeutics and USD 420 million for Treeline Biosciences. Biotechnology R&D accounted for roughly 17% of the USD 782 billion invested by the U.S. business sector in R&D in 2024.